Georgiamune Inc.

We're excited to announce the first participant has been dosed with our GIM-407 small molecule, the first selective T-regulatory cell activator, and our first in autoimmune disease program.? ? This is the third first-in-class asset in clinical trials since Georgiamune secured funding in nearly a year. We're proud to continue advancing novel science and research into treatments for patients with high unmet needs. To learn more about GIM-407, visit: https://lnkd.in/gYPhrMSt #biotech #clinicaltrial #autoimmunedisease

Today marks an important milestone for Georgiamune. We're proud to announce that the first cancer patient has been dosed with our GIM-531 drug. GIM-531 is a first-in-class, oral small-molecule cancer immunotherapy that selectively inhibits T regulatory cells. GIM-531 is designed to address indications and cancer types that are currently not addressed with existing or available immunotherapies.? ? This comes on the heels of GIM-122, a first-in-class dual-functioning antibody that's also already in clinical trials, treating cancer patients with high unmet needs. We're thrilled to now have two novel drugs in clinic less than a year from closing our Series A funding round. To learn more about GIM-531 and how Georgiamune is developing novel approaches to reach cancer and autoimmune disease patients around the world, visit: https://lnkd.in/gxpP_E7B #biotech #clinicaltrials #immunotherapies #cancer

We’re incredibly proud our CEO and Founder Samir Khleif was named a winner of the prestigious EY Entrepreneur of the Year Awards for his pioneering work and groundbreaking innovations in novel biology discoveries. Congratulations to the other finalists and winners!? ? To view all winners and learn more about the award, visit:?https://go.ey.com/4eHrqW7?#EYEntrepreneurOfTheYear #EYAwards #EYEOY #novelbiology

Big news from our team today! We're excited to announce that GIM-531 has received IND clearance from the FDA. GIM-531 is a first-in-class oral treatment that selectively targets T-regulatory cells, while sparing other immune cells like CD4 and CD8. That's in addition to GIM-122, our first-in-class, dual-functioning antibody, which is in human clinical trials.? ? We're proud to help propel novel science, and are another step closer to reprogramming immune signaling pathways to redirect the immune system to fight cancer and?autoimmune?diseases. Learn more: https://lnkd.in/gjtA5pRP #clinicaltrials #FDAclearance #cancer #firstinclass #noveldrugs

Founder and CEO Samir Khleif sat down with RJ Lumba on the Great Entrepreneurs Podcast. Hear Dr. Khleif shed light on his background, the origin of Georgiamune and our mission to reprogram immune signaling pathways to redirect the immune system to fight diseases. https://lnkd.in/gu7UMzsn? #biotech #hiring?